We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Article purchase
Temporarily unavailable
References
Bakker, C., Verboom, M. and Koopmans, R. (2022). Reimagining postdiagnostic care and support in young-onset dementia. Journal of American Medical Directors Association, 23, 261–265.CrossRefGoogle ScholarPubMed
Giebel, C., Cations, M., Draper, B. and Komuravelli, A. (2023). Ethnic disparities in the uptake of anti-dementia medication in young and late-onset dementia. International Psychogeriatrics, 35, 381–390.CrossRefGoogle Scholar
Iwatsubo, T. (2023). Editorial: clinical implementation of lecanemab: challenges, questions and solutions. The Journal of Prevention of Alzheimer’s Disease, 10, 353–355.Google ScholarPubMed
Loi, S. M.et al. (2022). Time to diagnosis in younger-onset dementia and the impact of a specialist diagnostic service. International Psychogeriatrics, 34, 367–375.CrossRefGoogle ScholarPubMed
Mendez, M. F. (2019). Early-onset Alzheimer disease and its variants. Continuum (Minneap Minn), 25, 34–51.Google ScholarPubMed
Ossenkoppele, R.et al. (2015). The behavioural/dysexecutive variant of alzheimer’s disease: clinical, neuroimaging and pathological features. Brain, 138, 2732–2749.CrossRefGoogle ScholarPubMed
Sabates, J.et al. (2023). The associations between neuropsychiatric symptoms and cognition in people with dementia: a systematic review and meta-analysis. Neuropsychology Review.Google ScholarPubMed
Seath, P., Macedo-Orrego, L. E. and Velayudhan, L. (2023). Clinical characteristics of early-onset versus late-onset Alzheimer’s disease: a systematic review and meta-analysis. International Psychogeriatrics, 1–17.Google ScholarPubMed
Sims, J. R.et al. (2023). Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 Randomized clinical trial. JAMA, 330, 512–527.CrossRefGoogle ScholarPubMed
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R. and Yokoyama, J. S. (2022). Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease. Molecular psychiatry, 27, 2674–2688.CrossRefGoogle ScholarPubMed
Van Dyck, C. H.et al. (2023). Lecanemab in early Alzheimer’s disease. The New England Journal of Medicine, 388, 9–21.CrossRefGoogle ScholarPubMed